Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia

Leukemia Research(2022)10.1016/j.leukres.2022.106872Source: DataRank Database

ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia is a research paper published in Leukemia Research (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.24)OA: greenTopics (29)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Chi‐Ling Chiang ORCID,Kevan Zapolnik ORCID,Jessica Nunes ORCID,Ann Ventura,Xiaokui Mo ORCID

Live enrichment

PubMed:35640397 OpenAlex:https://openalex.org/W4281976357

National Institutes of Health

Grant: 1F99CA245813-01

Protein Phosphatase PP2A and DNA damage in cell fate decisions of acute myeloid leukemic cells

National Institutes of Health

Grant: 5R01CA197844-04

Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia

National Institutes of Health

Grant: 3P30CA016058-15S1

CORE--HORMONE RECEPTOR LABORATORY

National Institutes of Health

Grant: 5P50CA140158-03

Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia

National Institutes of Health

Grant: 5R35CA197734-06

Targeted Therapy for Leukemia

FWCI

0.24

Citation Percentile

0.5%

Citation Trend

2023

2025

greenLicense: Elsevier TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10029232/pdf/nihms-1882499.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0145212622000984?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0145212622000984?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10029232

Fields of Study

RNA Interference and Gene DeliveryAcute Lymphoblastic Leukemia researchCAR-T cell therapy research03 medical and health sciences0302 clinical medicine

MeSH Terms

Burkitt LymphomaHumansPropylene GlycolsSphingosineTranslocation, GeneticPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptor Tyrosine Kinase-like Orphan Receptors

Keywords

CytotoxicityLymphoblastic LeukemiaLeukemiaCancer researchMedicineChemistryBiologyInternal medicineGeneticsIn vitroPropylene GlycolsSphingosineHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptor Tyrosine Kinase-like Orphan ReceptorsBurkitt LymphomaTranslocation, Genetic

Sustainable Development Goals

SDG 0: Good health and well-being